Fetal exposure to altered amniotic fluid glucose, insulin, and insulin-like growth factor-binding protein 1 occurs before screening for gestational diabetes mellitus

Daniel K Tisi, David H Burns, Gary W Luskey, Kristine G Koski, Daniel K Tisi, David H Burns, Gary W Luskey, Kristine G Koski

Abstract

Objective: We explored the possibility that perturbations in amniotic fluid glucose, insulin, and insulin-like growth factor-binding protein 1(IGFBP1) and/or metabolic acids exist before routine screening for GDM.

Research design and methods: We selected consenting mother-infant pairs (n = 408) who met our inclusion criteria (singleton pregnancy, no genetic abnormalities, and no preexisting diabetes) and for whom sufficient amniotic fluid and appropriate medical information were available. We compared birth outcomes and second trimester amniotic fluid glucose, insulin, IGFBP1 concentrations, and amniotic fluid lactic, β-hydroxybutyric, and uric acids of mothers with gestational diabetes mellitus (GDM) (n = 52) with those of mothers with no diagnosis of GDM at >24 weeks (n = 356).

Results: Higher amniotic fluid glucose, lactic acid, uric acid, and insulin and lower IGFBP1 concentrations were present by 15.1 ± 0.1 weeks in mothers in whom GDM was subsequently diagnosed. However, logistic regression showed that second trimester amniotic fluid glucose, but not insulin, IGFBP1, or metabolic acids was associated with an increased odds ratio (1.2 [95% CI 1.052-1.338]) for diagnosis of GDM at 24-28 weeks. In addition, probability contour maps that accounted for nonlinear relationships among the dynamically changing amniotic fluid constituents showed an increased risk for GDM with elevated second trimester amniotic fluid glucose in combination with either elevated amniotic fluid insulin or low amniotic fluid IGFBP1

Conclusions: Fetuses are exposed to increased amniotic fluid glucose before 15 weeks of gestation, suggesting that metabolic perturbations are underway before diagnosis and that earlier screening and intervention may be warranted.

Figures

Figure 1
Figure 1
A: Class-conditional Bayesian a posteriori probability density plotted as a contour map for amniotic fluid glucose paired with amniotic fluid insulin. B: Similar class-conditional Bayesian a posteriori probability density contour map for second trimester amniotic fluid glucose and IGFBP1. ○, mean for the population without GDM; +, mean for the population with GDM.

References

    1. Beardsall K, Diderholm BM, Dunger DB: Insulin and carbohydrate metabolism. Best Pract Res Clin Endocrinol Metab 2008;22:41–55
    1. Mulvihill SJ, Stone MM, Debas HT, Fonkalsrud EW: The role of amniotic fluid in fetal nutrition. J Pediat Surg 1985;20:668–672
    1. Dashe JS, Nathan L, McIntire DD, Leveno KJ: Correlation between amniotic fluid glucose concentration and amniotic fluid volume in pregnancy complicated by diabetes. Am J Obstet Gynecol 2000;182:901–904
    1. Star J, Canick JA, Palomaki GE, Carpenter MW, Saller DN, Jr, Sung CJ, Tumber MB, Coustan DR: The relationship between second-trimester amniotic fluid insulin and glucose levels and subsequent gestational diabetes. Prenat Diagn 1997;17:149–154
    1. D'Anna R, Baviera G, Cannata ML, De Vivo A, Di Benedetto A, Corrado F: Midtrimester amniotic fluid leptin and insulin levels and subsequent gestational diabetes. Gynecol Obstet Invest 2007;64:65–68
    1. Carpenter MW, Canick JA, Star J, Carr SR, Burke ME, Shahinian K: Fetal hyperinsulinism at 14–20 weeks and subsequent gestational diabetes. Obstet Gynecol 1996;87:89–93
    1. Hiden U, Glitzner E, Hartmann M, Desoye G: Insulin and the IGF system in the human placenta of normal and diabetic pregnancies. J Anat 2009;215:60–68
    1. Qiu C, Vadachkoria S, Meryman L, Frederick IO, Williams MA: Maternal plasma concentrations of IGF-1, IGFBP-1, and C-peptide in early pregnancy and subsequent risk of gestational diabetes mellitus. Am J Obstet Gynecol 2005;193:1691–1697
    1. Lindsay RS, Westgate JA, Beattie J, Pattison NS, Gamble G, Mildenhall LF, Breier BH, Johnstone FD: Inverse changes in fetal insulin-like growth factor (IGF)-1 and IGF binding protein-1 in association with higher birth weight in maternal diabetes. Clin Endocrinol (Oxf) 2007;66:322–329
    1. Reece EA: The fetal and maternal consequences of gestational diabetes mellitus. J Matern Fetal Neonatal Med 2010;23:199–203
    1. Egeland GM, Skjaerven R, Irgens LM: Birth characteristics of women who develop gestational diabetes: population based study. BMJ 2000;321:546–547
    1. Boisvert MR, Koski KG, Skinner CD: Increased oxidative modifications of amniotic fluid albumin in pregnancies associated with gestational diabetes mellitus. Anal Chem 2010;82:1133–1137
    1. Taricco E, Radaelli T, Rossi G, Nobile de Santis MS, Bulfamante GP, Avagliano L, Cetin I: Effects of gestational diabetes on fetal oxygen and glucose levels in vivo. BJOG 2009;116:1729–1735
    1. Pappa KI, Anagnou NP, Salamalekis E, Bikouvarakis S, Maropoulos G, Anogianaki N, Evangeliou A, Koumantakis E: Gestational diabetes exhibits lack of carnitine deficiency despite relatively low carnitine levels and alterations in ketogenesis. J Matern Fetal Neonatal Med 2005;17:63–68
    1. Roberts JM, Bodnar LM, Lain KY, Hubel CA, Markovic N, Ness RB, Powers RW: Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension 2005;46:1263–1269
    1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32:S1–S201
    1. MacKay D: Information Theory, Inference and Algorithms. second ed London, Cambridge University Press, 2003
    1. Carpenter MW, Canick JA, Hogan JW, Shellum C, Somers M, Star JA: Amniotic fluid insulin at 14–20 weeks' gestation: association with later maternal glucose intolerance and birth macrosomia. Diabetes Care 2001;24:1259–1263
    1. Polak M, Bouchareb-Banaei L, Scharfmann R, Czernichow P: Early pattern of differentiation in the human pancreas. Diabetes 2000;49:225–232
    1. Weiss PA, Hofmann H, Winter R, Pürstner P, Lichtenegger W: Amniotic fluid glucose values in normal and abnormal pregnancies. Obstet Gynecol 1985;65:333–339
    1. Weiss PA, Hofmann H, Pürstner P, Winter R, Lichtenegger W: Fetal insulin balance: gestational diabetes and postpartal screening. Obstet Gynecol 1984;64:65–68
    1. Westerway SC, Keogh J, Heard R, Morris J: Incidence of fetal macrosomia and birth complications in Chinese immigrant women. Aust NZ J Obstet Gynaecol 2003;43:46–49
    1. Loukovaara M, Leinonen P, Teramo K, Nurminen E, Andersson S, Rutanen EM: Effect of maternal diabetes on phosphorylation of insulin-like growth factor binding protein-1 in cord serum. Diabet Med 2005;22:434–439
    1. Schaefer-Graf UM, Kjos SL, Fauzan OH, Bühling KJ, Siebert G, Bührer C, Ladendorf B, Dudenhausen JW, Vetter K: A randomized trial evaluating a predominantly fetal growth-based strategy to guide management of gestational diabetes in Caucasian women. Diabetes Care 2004;27:297–302

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner